T he type 2 cytokines interleukin-4 (IL-4) and IL-13, which signal through IL-4 receptor alpha (IL-4Ra), trigger a specialized macrophage phenotype [M(IL-4)] (1) that promotes control of helminth infection (2) and tissue repair (3, 4) . M(IL-4)s also contribute to pathology associated with type 2 immunity, including allergy, asthma, and fibrosis (4) . However, little is known about tissue-specific factors that might promote both beneficial and detrimental actions of M(IL-4)s.
In the lung, alveolar macrophages (aMfs), together with the respiratory epithelium, are covered by pulmonary surfactant, a lipid-protein network in which surfactant protein A (SP-A) constitutes the major protein component (5) .
SP-A is a versatile recognition protein (5) that is a member of a group of secreted soluble defense collagens that include the first component of the complement system (C1q), collectins (e.g., SP-A, SP-D, mannan-binding lectin), ficolins, and adiponectin (6) . Because of its abundance and known role in immune defense (5), we asked whether SP-A was involved in the local regulation of M(IL-4) effector function in the lung.
M(IL-4)s have a critical role in lung repair after infection with the lung-migrating nematode Nippostrongylus brasiliensis (3). We therefore infected wild-type (WT), IL-4Ra-deficient, and SP-A-deficient mice with N. brasiliensis infective larvae. Larvae migrate to the lung, where they mature for ∼2 days, and reach the small intestine by 3 days postinfection (p.i.). The type 2 response peaks 6 to 7 days after inoculation. We observed an increase in the expression of SP-A protein (Fig. 1A) and mRNA (fig. S1A) in lungs of N. brasiliensis-infected C57BL/6 mice at 6 days p.i., which was dependent on IL-4Ra. Consistent with a role for SP-A during type 2 immunity to nematode infection, SP-A-deficient mice had greater adult worm burdens (Fig. 1B) and egg output (fig. S1B), and significantly impaired lung repair processes (Fig. 1, C and D) than WT mice. The failure to heal was associated with a failure to up-regulate tissue-repair-related gene Col1a1 (collagen, type I, alpha 1) (Fig. 1E ) and increased expression of Mmp12, an extracellular matrix-degrading enzyme (Fig. 1F) . Greater lung damage in SP-A-deficient mice was indicated by increased numbers of red blood cells and neutrophils in bronchoalveolar lavage (BAL) at 6 days p.i. (Fig. 1, G and H) . The absence of SP-A resulted in reduced expression of the M(IL-4) proteins RELMa (Fig. 1I) , Ym1, and arginase (fig. S1, C and D) in aMfs. Secretion of RELMa and Ym1 protein into the alveolar fluid ( fig. S1E ) was also reduced in SP-A-deficient mice as compared with WT mice.
Consistent with the known ability of IL-4 to cause macrophage proliferation during helminth infection (7), aMfs from WT mice exhibited significant proliferation (Fig. 1 , J and K) and increased aMf numbers (fig. S1F) 6 days after N. brasiliensis infection. However, SP-A-deficient mice failed to exhibit significantly enhanced aMf proliferation (Fig. 1, J and K) , resulting in fewer total macrophage numbers relative to WT mice ( fig. S1F ). There was no evidence that differences were caused by a failure of SP-A-deficient mice to mount appropriate type 2 innate lymphoid cell (ILC2), T helper 2 cell (T H 2) (fig. S1, G and H), or local type 2 cytokine responses ( fig. S1I) . Notably, aMfs from uninfected SP-A-deficient mice were normal in number, phenotype, and ability to respond to IL-4 ex vivo ( fig. S2, A to D) .
To ascertain if defects in SP-A-deficient mice were caused by defective IL-4Ra responsiveness in vivo, we injected WT and SP-A-deficient mice intraperitoneally (ip) with IL-4 complex (IL-4c). IL-4c delivery increased the amount of SP-A protein in BAL ( Enhancement of M(IL-4)s may underlie the previously reported contribution of SP-A to tissue integrity in other models of acute lung injury (8, 9) . The pro-type 2 effects we report here contrast with studies that associate SP-A with protection in asthma (10) . However, in addition to promoting M(IL-4) and proliferation of macrophages, the anti-inflammatory properties of SP-A (5, 6, 8, 9, 11) may suppress the strong inflammatory responses that are responsible for more severe asthma. Our data are supported by the finding that SP-D-deficient mice, which lack SP-A (12), also have reduced M(IL-4) responsiveness (13) .
To determine whether SP-A acts directly on aMfs, we first tested the ability of adherencepurified macrophages from the alveolar and peritoneal spaces to proliferate in vitro in response to IL-4 (1 mg/ml); aMfs exhibited significant proliferation, but peritoneal macrophages (pMfs) failed to proliferate despite expressing M(IL-4) activation markers ( fig. S4A ). We then tested the ability of SP-A to enhance IL-4 treatment and included C1q as a control because it is a defense collagen structurally homologous to SP-A (5, 6). We found that SP-A, but not C1q, significantly boosted IL-4-mediated aMf proliferation and M(IL-4) markers ( Fig. 2A) . IL-4Ra-deficient aMfs showed no proliferation or activation when stimulated with IL-4 (1 mg/ml) in the absence or presence of SP-A ( fig.  S4B ). Notably, SP-A significantly enhanced proliferation and activation induced by IL-4 in both human ( fig. S4C ) and rat aMfs ( fig. S4D) .
Unexpectedly, C1q, but not SP-A, significantly increased IL-4-mediated proliferation and M(IL-4) marker expression in pMfs ( Fig. 2A) . To verify these findings in vivo, IL-4c was delivered to C1qa-deficient mice. Consistent with the in vitro studies, mice lacking C1q exhibited reduced IL-4-dependent activation and proliferation in pMf but not aMf (Fig. 2B ). Similar to SP-A in the lung (Fig.  1L ), C1q levels increased in the peritoneal fluid after IL-4c delivery ( fig. S5A ), indicating that IL-4 drives production of a local signal to amplify its effect on tissue macrophages. Notably, the pMf phenotype, number, and ability to respond to IL-4 ex vivo are normal in C1qa-deficient mice ( fig.  S5 , B to F). Thus, SP-A and C1q were induced by IL-4 in the lung and peritoneal cavity, respectively, where they acted to enhance proliferation and M(IL-4) activation in a tissue-specific manner.
To determine which receptor mediates SP-A effects on IL-4-stimulated aMfs, we inhibited known receptors for SP-A (5). We observed that the blockade of myosin 18A (Myo18A; also called SP-R210), but not signal inhibitory regulatory protein a (SIRPa) or calreticulin (cC1qR), abrogated SP-A-mediated enhancement of IL-4-induced arginase activity in rat aMfs ( fig. S6A ). Blockade or RNA silencing of Myo18A consistently abolished SP-A-mediated enhancement of IL-4-induced proliferation and activation of mouse (Fig. 2C), human (fig. S6B ), and rat ( fig. S6C ) aMfs. Myo18A is an unconventional myosin that does not operate as a traditional molecular motor, having both intracellular and cell-surface locations (14) , and was recently defined as CD245 (15) . Immune activation results in Myo18A localization on the cell surface, where it binds to the collagen-like domain of SP-A (6, 16), and we confirmed that an intact collagen-like domain is required to enhance IL-4-mediated type 2 responses (fig. S6D ).
Because C1q is structurally homologous to SP-A in its supratrimeric assembly and collagen tail (5, 6), we addressed whether Myo18A was also responsible for the actions of C1q. Indeed, blockade of Myo18A prevented C1q enhancement of IL-4-driven activation and proliferation of pMfs (Fig. 2C) . In vitro, IL-4 promoted Myo18A localization on the cell surface of both aMfs and pMfs ( fig. S7, A and B) , which was maximal 24 hours after stimulation. Cell surface expression of Myo18A was similarly observed in vivo after IL-4c delivery (fig. S7, C and D), independent of the presence or absence of SP-A or C1q. We confirmed the role of Myo18A in vivo by intranasal or intraperitoneal delivery of antibodies against Myo18A (anti-Myo18A). Receptor blockade significantly reduced IL-4-induced proliferation and M(IL-4) activation of aMfs and pMfs (Fig. 2D) , as well as secretion of RELMa and Ym1 to the alveolar and peritoneal fluid (fig. S7, E and F). Thus, Myo18A receptor blockade in the lung or peritoneal cavity phenocopied SP-A or C1qa deficiency, respectively. Together these data indicate that Myo18A is a common receptor or co-receptor for defense collagens present on aMfs and pMfs, which determines macrophage capacity to respond to IL-4 and whose cell surface expression is itself induced by IL-4. Myo18A lacks a transmembrane domain (14) and thus must act in concert with transmembrane co-receptors for signal transduction that likely impart tissue specificity.
Unlike most other complement components, the majority of C1q is produced by myeloid cells in peripheral tissues (17) , supporting the relevance of C1q as a local factor that enhances type 2 responses. To determine the physiological relevance of C1q in this context, we evaluated its role in a murine model of peritoneal fibrosis (18) . Peritoneal fibrosis is a frequent and serious consequence of peritoneal dialysis (19) associated with alternatively activated macrophages in both humans and mice (18) (19) (20) . We administered Minutti Analysis of variance (ANOVA) followed by the Bonferroni multiple-comparison test was used. *P < 0.05, **P < 0.01, and ***P < 0.001 when compared with the untreated/uninfected group.°P < 0.05,°°P < 0.01, and°°°P < 0.001 when WT versus SP-A −/− groups are compared. Amplification of (D) Col1a1-and (E) Acta2-encoding mRNA in peritoneal tissue. Expression of (F) RELMa, (G) Ym1, (H) Arg, and (I) Ki67 by pMfs. Results are representative of two independent experiments (means ± SEM) (untreated: 3 mice, PD4: 6 mice). ANOVA followed by the Bonferroni multiple-comparison test or Student's t-test (A) was used. *P < 0.05, **P < 0.01, and ***P < 0.001 when compared with control group;°P < 0.05,°°P < 0.01, and°°°P < 0.001 when WT versus C1qa −/− mice treated with Dianeal-PD4 are compared.
Dianeal-PD4, a clinically used lactate-based dialysate, every other day for 28 days to WT, C1qa-deficient, and IL-4Ra-deficient mice. In WT, but not in C1qa-deficient mice, Dianeal-PD4 treatment provoked the induction of C1q (Fig. 3A) and morphologic changes in tissue sections of the parietal peritoneum, showing significant enlargement of the submesothelial zone caused by collagen deposition (Fig. 3, B and C) . Dianeal-PD4 treatment induced markers of fibrosis, including collagen mRNAs (Col1a1 and Col3a1) (Fig.  3D and fig. S8A ), alpha-smooth muscle actin (Acta2) (Fig. 3E) , and vascular endothelial growth factor (Vegf) (fig. S8B ). Substantial up-regulation of these markers was not observed in C1qa-deficient mice. Conversely, Mmp12 mRNA was up-regulated in C1qa-deficient mice relative to WT mice ( fig. S8C ), consistent with monocyte infiltration ( fig. S8D ) (21) and an anti-inflammatory role for C1q (22) . Dianeal-PD4 treatment also induced intracellular expression and protein secretion of the M(IL-4) markers RELMa, Ym1, and Arg (Fig. 3 , F to H) and moderate proliferation of pMfs (Fig. 3I ) in WT but not C1qa-deficient mice. Despite the clear induction of M(IL-4) markers by PD4 delivery and their dependence on C1q, responses of IL-4Ra-deficient mice were equivalent to those of WT mice (Fig. 3 , A to I, and fig. S8 , A to D). Although initially surprising, Dianeal-PD4 is a lactate-based solution, and lactate can induce M(IL-4) markers by acting downstream of IL-4Ra through stabilization of hypoxia-inducible factor alpha (HIF1a) protein (23) . Indeed, we observed that the induction of proliferation and M(IL-4) markers following Dianeal-PD4 delivery was essentially absent in mice lacking HIF1a in macrophages ( fig. S9 ). Together, our data indicate that C1q significantly amplifies peritoneal fibrosis by promoting a type 2 macrophage phenotype driven by lactate and dependent on HIF1a. These results are consistent with human studies in which C1q is strongly associated with increased fibrosis of skeletal muscle (24) . Critically, we sought to ascertain whether C1q functioned as a type 2 amplifier in tissues beyond the peritoneal cavity and settings that are dependent on IL-4Ra. We thus assessed Myo18A expression on the cell surface of resident macrophages from mice treated with or without IL-4c (Fig. 4A) . Consistent with our functional data, Myo18A was expressed in macrophages from the lung and peritoneal cavity, as well as in liver, spleen, and adipose tissue, and was significantly increased by IL-4 exposure. By contrast, there was minimal Myo18A on pleural cavity macrophages, which explained our failure to identify a role for C1q in the pleural cavity after IL-4c delivery ( fig. S10) . As predicted by the Myo18 expression data, we found that macrophages from the liver of C1qa-deficient mice had significantly lower levels of proliferation and M(IL-4) activation compared with WT mice following IL-4c delivery (Fig. 4B) . Notably, we observed C1q upregulation in the liver of IL-4c-treated mice (Fig.  4C) . Of relevance, the number and phenotype of liver macrophages are normal in C1qa-deficient mice ( fig. S11 ). Antibody blockade of Myo18A after IL-4 treatment of isolated liver macrophages verified that C1q generated its effects through Myo18A (fig. S12) . We thus sought a model in which M(IL-4)s in the liver played a substantive role.
Infection of the liver by the Gram-positive bacterium Listeria monocytogenes causes necroptotic death of resident liver macrophages (Kupffer cells) followed by recruitment of monocytes, which control L. monocytogenes infection (25) and repopulate the liver macrophage population (26) . After an initial type 1 response, the type 2 response begins at 3 days p.i., with IL-4-mediated activation and proliferation of liver macrophages acting to repair infection damage (26) . To ascertain the relevance of C1q and confirm the role of IL-4Ra in this process, we infected WT, C1qa-deficient, and IL-4Ra-deficient mice with L. monocytogenes and performed sample analysis 3.5 days later. Infection resulted in IL4Ra-dependent up-regulation of C1q mRNA in liver (Fig. 4C) , whereas enhanced expression of RELMa and Ym1 by liver macrophages (Fig. 4D  and fig. S13A ) and macrophage proliferation ( Fig. 4E and fig. S13B ) were dependent on both IL-4Ra and C1q. Consistent with the requirement for basophil-derived IL-4 in L. monocytogenesinduced liver macrophage proliferation (26), we observed increases in IL-4 and IL-13 cytokines in liver homogenates ( fig. S13C ). C1q and IL-4Ra deficiency were associated with increased liver injury as assessed by liver transaminases in blood (Fig. 4F) and a failure to up-regulate tissue-repairrelated genes (Acta2 and Col1a1) (Fig. 4G) . Notably, at 3.5 days p.i., liver bacterial burden was higher in WT than in C1qa-or IL-4Ra-deficient mice (Fig. 4H) . Gene-deficient mice had increased numbers of recruited monocytes (Fig. 4I) fig. S13F ). These data suggest that C1q, through its ability to orchestrate IL-4Ra-dependent type 2-mediated responses, decreases the bactericidal capacity of monocyte-derived macrophages but also limits liver injury and promotes the return to homeostasis (Fig. 4, D to I, and fig. S13 ).
M(IL-4)s have recently emerged as important players in homeostatic processes (27) , but IL4Ra-dependent pathways are amplified during helminth infection, with uncontrolled amplification leading to fibrosis (4, 28, 29) . Our data show that IL-4 drives production of local specific factors (SP-A and C1q) and expression of their receptor (Myo18A) on the macrophage surface for full M(IL-4) activation and proliferation ( fig. S14 ). These findings reveal the existence within distinct tissues of an amplification system needed for type 2 function. SP-A and C1q are typically produced by alveolar epithelial type II and myeloid cells, respectively, indicating that several different cell types must respond to IL-4 for signal amplification.
The study raises a number of critical questions. What are the Myo18A co-receptors that mediate tissue specificity? What factors negatively regulate or stop the positive M(IL-4) loop? What are the intracellular signaling pathways regulated by Myo18A and its co-receptors? Critically, SP-A, C1q, and Myo18A are highly conserved across mammalian species, and we have shown the ability of SP-A and Myo18A to enhance human alveolar M(IL-4) proliferation.
